Previous 10 | Next 10 |
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include...
Novan ( NASDAQ: NOVN ) has submitted a New Drug Application to the US FDA for berdazimer gel for the topical treatment of viral skin infection molluscum contagiosum. The submission is the first for the company. The application is supported by data from a phase 3 trial that showe...
Potential FDA approval anticipated in the first quarter of 2024, assuming FDA filing acceptance and standard review timelines Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, mostly children Berdazimer gel, 10.3% has the potential to be the firs...
Summary Ligand's spinoff of OmniAb has rightsized Ligand as it faces revenue challenges. Ligand's management changes should be productive for it. Several key catalysts are poised to enhance its portfolio to address expected revenue reductions. My inaugural Ligand (LGND) ...
Executive Management Reviewed Business Model and Growth Drivers Following the Successful Spin-Off of OmniAb, Introduced 2023 Financial Guidance Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today’s Investor and Analyst Day event its executive management...
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it will share a poster presentation a...
John Higgins Retires as CEO and will Resign from the Ligand Board of Directors Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that John Higgins has retired as Chief Executive Officer, effective as of today, and that the company’s board of directors has nam...
3 Hot Penny Stocks To Buy For Under $3, Worth It? Penny stocks are some of the most volatile assets in the stock market today. But is the risk worth the reward? That’s something traders grapple with daily. One unique thing about 2022 is that there are far more companies with shar...
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1 -mutated metastatic breast and gynecological cancers, today announced that it had four abstr...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time). A live and archived webcast will be avai...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-09 10:30:11 ET Craig-Hallum analyst issues BUY recommendation for LGND on July 9, 2024 08:42AM ET. The previous analyst recommendation was Buy. LGND was trading at $86.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-07-09 10:00:05 ET Matt Hewitt from Craig-Hallum issued a price target of $140.00 for LGND on 2024-07-09 08:42:00. The adjusted price target was set to $140.00. At the time of the announcement, LGND was trading at $86.88. The overall price target consensus is at $117...
Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the b...